Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows great clinical activity in non-small cell lung cancer (NSCLC) patients with EGFR mutations regardless of T790M mutation at first-line chemotherapy. Previous studies demonstrated that there...

Descripción completa

Detalles Bibliográficos
Autores principales: Nozaki, Koichiro, Watanabe, Satoshi, Nishio, Kazuto, Sakai, Kazuko, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841509/
https://www.ncbi.nlm.nih.gov/pubmed/35261905
http://dx.doi.org/10.21037/tcr-21-1850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841509/
https://www.ncbi.nlm.nih.gov/pubmed/35261905
http://dx.doi.org/10.21037/tcr-21-1850

Ejemplares similares